Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Woong Lee, Jung Hyun Kwon, Moon Young Kim, Do Seon Song, Jung Gil Park, Yoon Seok Lee, Eileen L. Yoon, Han Ah Lee, Seong Hee Kang, Jin Mo Yang
Clin Mol Hepatol 2025;31(3):810-822. Published online January 17, 2025
Background/Aims Besifovir (BSV) showed comparable antiviral activity and superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral efficacy and safety of BSV in patients with CHB who switched from long-term TDF to BSV. This study aimed to evaluate the outcome of a 48-week BSV therapy in patients with CHB who switched from long-term TDF treatment.
Methods In this non-inferiority trial, 153 CHB patients treated with TDF for ≥48 weeks who had hepatitis B virus (HBV) DNA <20 IU/mL were randomized to receive either BSV 150 mg or TDF 300 mg for 48 weeks.
Results The per-protocol analysis included 130 patients (BSV group, 64; TDF group, 66). The median duration of TDF use before enrollment was 4.14 years. After 48 weeks, 100.0% and 98.5% patients in the BSV and TDF groups, respectively, met the primary endpoint (HBV DNA <20 IU/mL), demonstrating the non-inferior antiviral efficacy of BSV to TDF (95% confidence interval –0.01 to 0.04; P>0.999), with a predefined margin of –0.18. The mean percentage changes in estimated glomerular filtration rates were slightly better in the BSV group (1.67±11.73%) than in the TDF group (–1.24±11.02%). The BSV group showed a significant improvement in bone turnover biomarkers compared to the TDF group; accordingly, hip and spine bone mineral density increased in the BSV group.
Conclusions In patients with CHB receiving long-term TDF, switching to BSV may improve renal and bone safety with non-inferior antiviral efficacy compared to that of maintaining TDF.
Citations
Citations to this article as recorded by
Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial” Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang Clinical and Molecular Hepatology.2026; 32(1): e55. CrossRef
Besifovir: a viable option for long-term disease control in chronic hepatitis B: Editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial” Wai-Kay Seto Clinical and Molecular Hepatology.2026; 32(1): 374. CrossRef
Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu, Zhen-Yu Xu World Journal of Gastroenterology.2025;[Epub] CrossRef
Background/Aims Bariatric intervention has been reported to be an effective way to improve metabolic dysfunction-associated steatotic liver disease (MASLD) in obese individuals. The current systemic review aimed to assess the changes in MRI-determined hepatic proton density fat fraction (MRI-PDFF) and nonalcoholic fatty liver disease activity score (NAS) after bariatric surgery or intragastric balloon/gastric banding in MASLD patients with obesity.
Methods We searched various databases including PubMed, OVID Medline, EMBASE, and Cochrane Library. Primary outcomes were the changes in intrahepatic fat on MRI-PDFF and histologic features of metabolic dysfunction-associated steatohepatitis (MASH).
Results Thirty studies with a total of 3,134 patients were selected for meta-analysis. Bariatric intervention significantly reduced BMI (ratio of means, 0.79) and showed 72% reduction of intrahepatic fat on MRI-PDFF at 6 months after bariatric intervention (ratio of means, 0.28). Eight studies revealed that NAS was reduced by 60% at 3–6 months compared to baseline, 40% at 12–24 months, and 50% at 36–60 months. Nineteen studies revealed that the proportion of patients with steatosis decreased by 44% at 3–6 months, 37% at 12–24 months, and 29% at 36–60 months; lobular inflammation by 36% at 12–24 months and 51% at 36–60 months; ballooning degeneration by 38% at 12–24 months; significant fibrosis (≥F2) by 18% at 12–24 months and by 17% at 36–60 months after intervention.
Conclusions Bariatric intervention significantly improved MRI-PDFF and histologic features of MASH in patients with obesity. Bariatric intervention might be the effective alternative treatment option for patients with MASLD who do not respond to lifestyle modification or medical treatment.
Citations
Citations to this article as recorded by
Serial changes in metabolic dysfunction-associated steatotic liver disease after sleeve gastrectomy and their associations with abdominal adiposity: a prospective cohort study Chung-Yi Yang, Jian-Han Chen, Chung-Yen Chen, Cheng-Yi Kao, Shiu-Feng Huang, Wen-Yu Chang, Hung-Pin Tu, Jee-Fu Huang, Ming-Lung Yu, Chi-Ming Tai Surgery for Obesity and Related Diseases.2025; 21(5): 537. CrossRef
Bariatric nutrition and evaluation of the metabolic surgical patient: Update to the 2022 Obesity Medicine Association (OMA) bariatric surgery, gastrointestinal hormones, and the microbiome clinical practice statement (CPS) Sue Benson-Davies, Kirsten Frederiksen, Rutuja Patel Obesity Pillars.2025; 13: 100154. CrossRef
Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis” Xiao-Song Li, Xi-Ping Shen, Hang Li Clinical and Molecular Hepatology.2025; 31(1): e15. CrossRef
Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis” Yuri Cho, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(1): e103. CrossRef
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot Eda Kaya, Wing-Kin Syn, Paul Manka Current Opinion in Gastroenterology.2025; 41(3): 104. CrossRef
Perioperative Screening for Metabolic Dysfunction Associated Steatotic Liver Disease in People Undergoing Bariatric Surgery: A Pilot Study David M. Williams, Thinzar Min, Andrew Beamish, Jeffrey W. Stephens Obesity Surgery.2025; 35(5): 1963. CrossRef
Impact of Severity of Metabolism-Related Fatty Liver Disease Based on Pathologic Grading on Outcomes after Sleeve Gastrectomy 云飞 曲 Journal of Clinical Personalized Medicine.2025; 04(02): 826. CrossRef
Cambios biométricos y metabólicos a un año de seguimiento en pacientes con obesidad e hígado graso sometidos a gastroplastia endoscópica en manga-EndoSleeve (método Apollo) Diego Schwarzstein, Lissette Batista, Patricia Gonçalves, Luis Yip, Leoniana Bustillos, Mar Bacardit, Josep Merlo Revista de la Sociedad Española de Cirugía de Obesidad y Metabólica y de la Sociedad Española para el Estudio de la Obesidad.2025;[Epub] CrossRef
Liver and obesity: a narrative review Amedeo Lonardo, Ralf Weiskirchen Exploration of Medicine.2025;[Epub] CrossRef
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders Marwin A. Farrugia, Enzo Pini, Albert Tran, Nicolas Chevalier, Rodolphe Anty, Philippe Gual Current Obesity Reports.2025;[Epub] CrossRef
Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Chih-Cheng Lai Hepatology International.2025; 19(5): 1087. CrossRef
Exploring the role of xanthine oxidase and aldehyde oxidase in metabolic dysfunction-associated steatotic liver disease (MASLD) Neha Gupta, Kavita Singh Journal of Molecular Histology.2025;[Epub] CrossRef
Diabetes mellitus as a multisystem disease: understanding subtypes, complications, and the link with steatotic liver diseases in humans Anna Giannakogeorgou, Michael Roden, Kalliopi Pafili Hormones.2025;[Epub] CrossRef
Duodenal mucosal ablation: An emerging therapeutic concept for metabolic dysfunction-associated fatty liver disease Cornelius J Fernandez, Sweekruti Jena, Vijaya Lakshmi, Joseph M Pappachan World Journal of Gastroenterology.2025;[Epub] CrossRef
Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet–induced Mouse Model Huimin Xia, Yuqin Min, Yuhua Wang, Siyu Gao, Hailing Wang, Fuhua Yan, Ruixin Liu, Jiqiu Wang, Xuejiang Gu, Tingting Bo Radiology.2025;[Epub] CrossRef
Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era Dragoș Lupu, Camelia Cornelia Scârneciu, Diana Țînț, Cristina Tudoran Journal of Clinical Medicine.2025; 14(17): 5993. CrossRef
ISImatsuda as a potential predictor of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus Jing Liu, Yueqiu Wang, Xinghang Zhou, Zaixin Wen, Yu Chen, Yiqiong Sun, Shuaiying Su, Weiwei Lin, Ruiting Shen, Xiaoyu Sun, Hongru Li, Xia Yu, Mingchen Zhang Frontiers in Medicine.2025;[Epub] CrossRef
Connecting the Dots: Hepatic Steatosis as a Central Player in the Choreography of the Liver-Cardiovascular-Kidney-Metabolic Syndrome Richard H. Goodheart, Oyekoya T. Ayonrinde Heart, Lung and Circulation.2025; 34(10): 1050. CrossRef
Prospective evaluation of a structured group education programme for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) Thomas Crame, Rachel Howarth, Elizabeth Johnstone, Hollie Smith, Stuart McPherson, Kate Hallsworth Frontline Gastroenterology.2025; : flgastro-2025-103280. CrossRef
Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications Wissam Ghusn, Mira Sridharan, Rachel Fromer, Muhammet Ozdemir, Madeleine G. Haff, Eric J. Vargas Biomedicines.2025; 13(10): 2437. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults Herbert Tilg, Salvatore Petta, Norbert Stefan, Giovanni Targher JAMA.2025;[Epub] CrossRef
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG Chinese Journal of Natural Medicines.2024; 22(8): 724. CrossRef
Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study José Ignacio Martínez-Montoro, Isabel Arranz-Salas, Carolina Gutiérrez-Repiso, Ana Sánchez-García, Luis Ocaña-Wilhelmi, José M. Pinazo-Bandera, Diego Fernández-García, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés, Eduardo García-Fuente Nutrients.2024; 16(22): 3857. CrossRef
Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi
Clin Mol Hepatol 2022;28(3):540-552. Published online May 6, 2022
Background/Aims Sepsis-3 criteria and quick Sequential Organ Failure Assessment (qSOFA) have been advocated to be used in defining sepsis in the general population. We aimed to compare the Sepsis-3 criteria and Chronic Liver Failure-SOFA (CLIF-SOFA) scores as predictors of in-hospital mortality in cirrhotic patients admitted to the emergency department (ED) for infections.
Methods A total of 1,622 cirrhosis patients admitted at the ED for infections were assessed retrospectively. We analyzed their demographic, laboratory, and microbiological data upon diagnosis of the infection. The primary endpoint was inhospital mortality rate. The predictive performances of baseline CLIF-SOFA, Sepsis-3, and qSOFA scores for in-hospital mortality were evaluated.
Results The CLIF-SOFA score proved to be significantly better in predicting in-hospital mortality (area under the receiver operating characteristic curve [AUROC], 0.80; 95% confidence interval [CI], 0.78–0.82) than the Sepsis-3 (AUROC, 0.75; 95% CI, 0.72–0.77, P<0.001) and qSOFA (AUROC, 0.67; 95% CI, 0.64–0.70; P<0.001) score. The CLIF-SOFA, CLIF-C-AD scores, Sepsis-3 criteria, septic shock, and qSOFA positivity were significantly associated with in-hospital mortality (adjusted hazard ratio [aHR], 1.24; 95% CI, 1.19–1.28; aHR, 1.13; 95% CI, 1.09–1.17; aHR, 1.19; 95% CI, 1.15–1.24; aHR, 1.88; 95% CI, 1.42–2.48; aHR, 2.06; 95% CI, 1.55–2.72; respectively; all P<0.001). For CLIF-SOFA scores ≥6, in-hospital mortality was >10%; this is the cutoff point for the definition of sepsis.
Conclusions Among cirrhosis patients presenting with infections at the ED, CLIF-SOFA scores showed a better predictive performance for mortality than both Sepsis-3 criteria and qSOFA scores, and can be a useful tool of risk stratification in cirrhotic patients requiring timely intervention for infection.
Citations
Citations to this article as recorded by
A Serum DLL1 and CRP dual-marker model for bacterial infection detection in patients with decompensated cirrhosis: A dual-cohort diagnostic study Juanjun Huang, Luhu Yu, Debin Zeng, Yulin Wang, Zhi Wang, Jian Chen, Wei Zhu Science Progress.2025;[Epub] CrossRef
Correlation between systemic inflammatory response syndrome and prognosis of patients with cirrhosis and hepatic encephalopathy Kaiyue Zhang, Ziqun Qu, Rongyu Tang, Hongliang Dong, Jing Fan, Wei Ye BMC Gastroenterology.2025;[Epub] CrossRef
Management of patients with cirrhosis in the emergency department: Implications for hospitalization outcomes Sandeep Sikerwar, Sohrab Zand, Peter Steel, Arun Jesudian Liver Transplantation.2024; 30(1): 94. CrossRef
Current Status of Prognostic Evaluation Model and Treatment of Acute-on-Chronic Liver Failure 念 刘 Advances in Clinical Medicine.2024; 14(04): 2500. CrossRef
Prevalence and predictors of multidrug-resistant bacteremia in liver cirrhosis Aryoung Kim, Byeong Geun Song, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Myung Ji Goh The Korean Journal of Internal Medicine.2024; 39(3): 448. CrossRef
Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Ya Clinical and Molecular Hepatology.2024; 30(3): 388. CrossRef
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment” Do Seon Song, Dong Joon Kim Clinical and Molecular Hepatology.2024; 30(4): 1012. CrossRef
Cirrhosis Management in the Intensive Care Unit Thomas N. Smith, Alice Gallo de Moraes, Douglas A. Simonetto Seminars in Liver Disease.2023; 43(01): 117. CrossRef
Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2021;27(3):363-401. Published online June 22, 2021
Quinoa bran terpenoids ameliorates metabolic dysfunction-associated steatotic liver disease by enriching of L. murinus LQ719 Qinqin Qiao, Shuhua Shan, Huiqin Guo, Ning An, Jiangying Shi, Zhuoyu Li Food Research International.2026; 225: 118084. CrossRef
Effects of Intermittent Calorie Restriction in Nondiabetic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Han Ah Lee, Hyeyoung Moon, Yuri Kim, Jeong Kyong Lee, Hye Ah Lee, Hwi Young Kim Clinical Gastroenterology and Hepatology.2025; 23(1): 114. CrossRef
Serum Ferritin Levels and Liver‐Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Alimentary Pharmacology & Therapeutics.2025; 61(3): 491. CrossRef
Differential Exercise Requirements for Nonalcoholic Fatty Liver Disease Resolution Across Age Groups: A Longitudinal Study of Korean Military Officers Jaejun Lee, Dong Yeup Lee, Jae Hyeop Jung, Eunkyoung Bae, Jeong A. Yu, Hyun Yang Journal of Physical Activity and Health.2025; 22(3): 323. CrossRef
The Role of microRNA-22 in Metabolism Simone Tomasini, Paolo Vigo, Francesco Margiotta, Ulrik Søberg Scheele, Riccardo Panella, Sakari Kauppinen International Journal of Molecular Sciences.2025; 26(2): 782. CrossRef
Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults Jaejun Lee, Chang In Han, Dong Yeup Lee, Pil Soo Sung, Si Hyun Bae, Hyun Yang Gut and Liver.2025; 19(1): 116. CrossRef
Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease Mei-jing Chen, Ying Chen, Jin-qing Lin, Rong Hu, Dun Liu, Jing-yi Chen, Ka Li, Xiao-ying Jiang Frontiers in Nutrition.2025;[Epub] CrossRef
Diagnostic Accuracy of Non-Invasive Diagnostic Tests for Nonalcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis Yuxin Sun, Die Hu, Mingkun Yu, Shi-Bing Liang, Youyou Zheng, Xin Wang, Guangdong Tong Clinical Epidemiology.2025; Volume 17: 53. CrossRef
Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim American Journal of Gastroenterology.2025; 120(10): 2321. CrossRef
Comparing non-alcoholic fatty liver disease indices in predicting the prevalence and incidence of metabolic syndrome in middle-aged adults Byung Sik Kim, Hyun-Jin Kim, Seong Won Jeon, Kyung Hwan Kim, Dong Wook Kim, Jeong-Hun Shin Heliyon.2025; 11(7): e43073. CrossRef
Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort study Huiyul Park, Terry Cheuk-Fung Yip, Eileen L. Yoon, Grace Lai-Hung Wong, Hye Sun Lee, Vincent Wai-Sun Wong, Jimmy Che-To Lai, Dae Won Jun JHEP Reports.2025; 7(6): 101388. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang BMC Gastroenterology.2025;[Epub] CrossRef
Sex differences in the mediation of the MASLD - Depression association by fat distribution in U.S. adults Changhuai He, Liuxin Zhou, Tianming Gao, Runmin Cao, Chuanqi Cai, Guoqing Jiang Acta Psychologica.2025; 256: 105041. CrossRef
Association Between Perfluoroalkyl Substance (PFAS) Exposure and Nonalcoholic Fatty Liver Disease in Korean Adults: Results From the KoNEHS 2018–2020: A Cross‐Sectional Study Jisuk Yun, Young‐Sun Min American Journal of Industrial Medicine.2025; 68(7): 588. CrossRef
Valorization of grape pomace by microbial fermentation: Composition, biological activities and potential applications for the food industry Kavindya Samarakoon, H.P. Vasantha Rupasinghe Journal of Food Composition and Analysis.2025; 144: 107656. CrossRef
Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review Vignesh Rajan, Ambarish Das, J. Venkatachalam, K. K. Lohani, Chandrakant Lahariya Preventive Medicine: Research & Reviews.2025; 2(4): 183. CrossRef
Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up Mimi Kim, Huiyul Park, Eileen L. Yoon, Ramsey Cheung, Donghee Kim, Hye-Lin Kim, Dae Won Jun Scientific Reports.2025;[Epub] CrossRef
Are mesenchymal stem/stromal cells a novel avenue for the treatment of non-alcoholic fatty liver disease? Milton Artur Ruiz, Roberto Luiz R Kaiser Junior, Gabriel Piron-Ruiz, Luiz Gustavo de Quadros World Journal of Stem Cells.2025;[Epub] CrossRef
The ameliorative effect of C-Kit+ hepatic endothelial cells with Mertk deficiency on nonalcoholic steatohepatitis Seng-Wang Fu, Yu-Xuan Gao, Hui-Yi Li, Jun-Cheng Wu, Zheng-Hong Li, Ming-Yi Xu Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(7): 167964. CrossRef
Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease Eiji Kakazu, Masaaki Mino, Tatsuya Kanto Clinical and Molecular Hepatology.2025; 31(3): 771. CrossRef
Chemical profile of Ficus lyrata bark extract and its therapeutic effect on non-alcoholic fatty liver disease via regulating oxidative stress, inflammation and hepatic lipogenesis Amria Mamdouh Mousa, Rehab Fikry Taher, Nermin Mohamed El-Sammad, Esraa Aly Balabel, Elham Mohamed Youssef, Ahmed Hassan Afifi, Sahar Samir Abdel-Rahman, Nayera Anwar, Sherien Kamal Hassan BMC Complementary Medicine and Therapies.2025;[Epub] CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study Minkwan Kim, Minkook Son, Sang Yi Moon, Yang Hyun Baek Journal of the American Heart Association.2025;[Epub] CrossRef
Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease Inyoung Hwang, Shi-Ra Lee, Yun Kim, Sang Won Lee Frontiers in Medicine.2025;[Epub] CrossRef
Exercise training improves metabolic and circulatory function in COPD patients with NAFLD: evidence from clinical and molecular profiling Yi-cai Qian, Xiaoxiang Liu, Panpan Liu, ShuYing Jia, Yi Ding, Cuiling Zhu, Jing He Frontiers in Medicine.2025;[Epub] CrossRef
Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gut and Liver.2025; 19(5): 758. CrossRef
Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review Muhammad Y. Sheikh, Muhammad F. Younus, Annie Shergill, Muhammad N. Hasan International Journal of Molecular Sciences.2025; 26(19): 9625. CrossRef
Association of Rapid Early Weight Loss with One-Year Hepatic Steatosis Improvement After Sleeve Gastrectomy: A Retrospective Cohort Study Min Kyoung Jang, Si Yeol Yoon, Jin A. An, Ji Soo Kim, Min-Seon Kim, Jung Ah Lee, Chang Seok Ko, Se Hee Min Journal of Clinical Medicine.2025; 14(20): 7284. CrossRef
Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges Walaa Abdelhamed, Mona Amin, Imam Waked, Mohamed El-Kassas World Journal of Gastroenterology.2025;[Epub] CrossRef
Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim The Journal of Infectious Diseases.2024; 229(1): 108. CrossRef
A Comparison of the Prognostic Value of Liver Fibrosis Scores in Acute Myocardial Infarction Patients With and Without Type 2 Diabetes Hao-ming He, Shu-wen Zheng, Yi-nong Chen, Long-yang Zhu, Zhe Wang, Si-qi Jiao, Fu-rong Yang, Yi-hong Sun Angiology.2024; 75(3): 219. CrossRef
Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style Qianying Zuo, Nicole Hwajin Park, Jenna Kathryn Lee, Ashlie Santaliz-Casiano, Zeynep Madak-Erdogan Steroids.2024; 203: 109330. CrossRef
Association between plant-based diets and risk of metabolic dysfunction–associated steatotic liver disease in Korean adults: A prospective cohort study Bayarmaa Nasan Ulzii, Kyungjoon Lim, Sangah Shin Nutrition.2024; 128: 112579. CrossRef
Extrahepatic malignancies in metabolic dysfunction‐associated fatty liver disease: A nationwide cohort study Min Kyung Park, Moon Haeng Hur, Hye‐Sung Moon, Hyunjae Shin, Sung Won Chung, Sungho Won, Yun Bin Lee, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Jung‐Hwan Yoon, Yoon Jun Kim Liver International.2024; 44(3): 799. CrossRef
Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease Anna Stefanska, Katarzyna Bergmann, Szymon Suwała, Aneta Mankowska-Cyl, Marek Kozinski, Roman Junik, Magdalena Krintus, Mauro Panteghini Metabolites.2024; 14(1): 52. CrossRef
Very low-carbohydrate diet with higher protein ratio improves lipid metabolism and inflammation in rats with diet-induced nonalcoholic fatty liver disease I-Ting Wu, Wan-Ju Yeh, Wen-Chih Huang, Hsin-Yi Yang The Journal of Nutritional Biochemistry.2024; 126: 109583. CrossRef
Quality Evaluation of Metabolic-Associated Fatty Liver Disease
Guidelines and Expert Consensus Meijing Chen, Ying Chen, Dun Liu, Ka Li, Rong Hu, Jingyi Chen, Xiaoying Jiang, Jinqing Lin Hormone and Metabolic Research.2024; 56(07): 509. CrossRef
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies Xin Ding, Xu He, Bulang Tang, Tian Lan Chinese Medicine.2024;[Epub] CrossRef
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Soo Lim, Woojoo Lee, Won Kim JAMA Internal Medicine.2024; 184(4): 375. CrossRef
Mobile App–Based Lifestyle Coaching Intervention for Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial Oh Young Kwon, Mi Kyung Lee, Hye Won Lee, Hyerang Kim, Jae Seung Lee, Yeonsoo Jang Journal of Medical Internet Research.2024; 26: e49839. CrossRef
Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective Jia-Lan Wang, Su-Wen Jiang, Ai-Rong Hu, Ai-Wu Zhou, Ting Hu, Hong-Shan Li, Ying Fan, Ken Lin Heliyon.2024; 10(5): e27325. CrossRef
Assessment of Hepatic Steatosis Using Ultrasound-Based Techniques: Focus on Fat Quantification Woo Sun Rou Clinical Ultrasound.2024; 9(1): 1. CrossRef
Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon Gut and Liver.2024; 18(2): 294. CrossRef
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi Liver International.2024; 44(6): 1448. CrossRef
Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease Yaxin Li, Yitian Guo, Shiyun Tan Clinics and Research in Hepatology and Gastroenterology.2024; 48(4): 102320. CrossRef
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Liver Cancer.2024; 13(5): 561. CrossRef
Sleep factors were associated with a higher risk of MAFLD and significant fibrosis Yaxin Li, Shiyun Tan Sleep and Breathing.2024; 28(3): 1381. CrossRef
Puerarin Induces Macrophage M2 Polarization to Exert Antinonalcoholic Steatohepatitis Pharmacological Activity via the Activation of Autophagy Xiaoxue Fang, Xintian Lan, Ming Zhu, Min He, Mengmeng Sun, Yiming Cao, Difu Zhu, Dean Guo, Haoming Luo Journal of Agricultural and Food Chemistry.2024; 72(13): 7187. CrossRef
Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score Aryoung Kim, Danbee Kang, Sung Chul Choi, Juhee Cho, Dong Hyun Sinn, Geum-Youn Gwak, Ashraf Elbahrawy PLOS ONE.2024; 19(3): e0301126. CrossRef
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim Yonsei Medical Journal.2024; 65(7): 371. CrossRef
Diagnostic performances of Fibrosis‐4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction‐associated steatotic liver disease in Asian primary care clinics Huiyul Park, Mimi Kim, Hye‐Lin Kim, Seon Cho, Eileen L. Yoon, Dae Won Jun Hepatology Research.2024; 54(11): 1027. CrossRef
Harnessing Metabolic Indices as a Predictive Tool for Cardiovascular Disease in a Korean Population without Known Major Cardiovascular Event Hyun-Jin Kim, Byung Sik Kim, Yonggu Lee, Sang Bong Ahn, Dong Wook Kim, Jeong-Hun Shin Diabetes & Metabolism Journal.2024; 48(3): 449. CrossRef
An Exploration of the Treatment of Non-Alcoholic Fatty Liver Disease Based on Dietary Factors Wanzhou Yang, Y.-T. Yu, P.P. Piccaluga, S. Xie BIO Web of Conferences.2024; 111: 03024. CrossRef
Assessing the Utility of Acoustic Radiation Force Impulse in the Evaluation of Non-Alcoholic Fatty Liver Disease with Severe Obesity or Steatosis Yeo Wool Kang, Yang Hyun Baek, Jong Hoon Lee, Young Hoon Roh, Hee Jin Kwon, Sang Yi Moon, Min Kook Son, Jin Sook Jeong Diagnostics.2024; 14(11): 1083. CrossRef
Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort Joo Hyun Oh, Sang Bong Ahn, Seon Cho, Eun-Hee Nah, Eileen L. Yoon, Dae Won Jun Journal of Hepatology.2024; 81(5): 772. CrossRef
A Novel Antioxidant, Hydrogen-Rich Coral Calcium Alters Gut Microbiome and Bile Acid Synthesis to Improve Methionine-and-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease Hung-Tsung Wu, Chin-Shiang Tsai, Ting-Hsing Chao, Horng-Yih Ou, Liang-Miin Tsai Antioxidants.2024; 13(6): 746. CrossRef
Evaluation of pancreatic iodine uptake and related influential factors in multiphase dual-energy CT Chen Pan, Tao Yu, Heng Zhao, Jiani He, Xiaomei Lu, Haiyan Tang, Yang Hong, Chao Shang, Qijun Wu, Aoran Yang, Chunli Li, Minghui Zhou, Yu Shi European Radiology.2024; 34(12): 7609. CrossRef
Comparative effects of lifelong moderate-intensity continuous training and high-intensity interval training on blood lipid levels and mental well-being in naturally ageing mice Ling Yang, Wentao Lin, Xu Yan, Zhishang Zhang Experimental Gerontology.2024; 194: 112519. CrossRef
The Effect of Mobile Lifestyle Intervention Combined with High-Protein Meal Replacement on Liver Function in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Randomized Controlled Trial Eunbyul Cho, Sunwoo Kim, Soonkyu Kim, Ju Young Kim, Hwa Jung Kim, Yumi Go, Yu Jung Lee, Haesol Lee, Siye Gil, Sung Kwon Yoon, Keonho Chu Nutrients.2024; 16(14): 2254. CrossRef
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients Maria Eva Argenziano, Mi Na Kim, Michele Montori, Alessandro Di Bucchianico, Daniele Balducci, Sang Hoon Ahn, Gianluca Svegliati Baroni Hepatology International.2024; 18(S2): 922. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Gastroenterology.2024; 84(1): 1. CrossRef
Barriers to care linkage and educational impact on unnecessary MASLD referrals Jun-Hyuk Lee, Eileen Laurel Yoon, Ju Hyun Oh, Kyunam Kim, Sang Bong Ahn, Dae Won Jun Frontiers in Medicine.2024;[Epub] CrossRef
Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes Merve Cebi, Yusuf Yilmaz Frontiers in Immunology.2024;[Epub] CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Medicine.2024; 99(4): 189. CrossRef
Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction‐associated steatotic liver disease Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Alimentary Pharmacology & Therapeutics.2024; 60(8): 1051. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
A new Korean nomenclature for steatotic liver disease
Clinical and Molecular Hepatology.2024; 30(Suppl): S214. CrossRef
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599. CrossRef
Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification Min Kyu Kang, Jeong Eun Song, Rohit Loomba, Soo Young Park, Won Young Tak, Young Oh Kweon, Yu Rim Lee, Jung Gil Park Scientific Reports.2024;[Epub] CrossRef
A narrative review of lifestyle management guidelines for metabolic dysfunction–associated steatotic liver disease Dana Ivancovsky Wajcman, Christopher J. Byrne, John F. Dillon, Paul N. Brennan, Marcela Villota-Rivas, Zobair M. Younossi, Alina M. Allen, Javier Crespo, Lynn H. Gerber, Jeffrey V. Lazarus Hepatology.2024;[Epub] CrossRef
Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Min Kyu Kang, Jeung Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Yu Rim Lee, Jung Gil Park Diagnostics.2024; 14(20): 2305. CrossRef
Pathogenesis and management of metabolic dysfunction-associated
steatohepatitis-related hepatocellular carcinoma: a narrative
review Han Ah Lee The Ewha Medical Journal.2024;[Epub] CrossRef
Evaluation of hepatoprotective and nephroprotective activities of Castanopsis costata extract in rats Maulana Alkandahri, Asman Sadino, Ermi Abriyani, Faizal Hermanto, Zulpakor Oktoba, Muhammad Sayoeti, Putu Sangging, Diah Wardani, Nahrul Hasan, Suci Sari, Nurul Safitri, Windi Ikhtianingsih, Safitri Safitri Biomedical Reports.2024;[Epub] CrossRef
Cross-talk between gut microbiota and liver steatosis: Complications and therapeutic target Yuan Yao, Yunfeng Shen Open Life Sciences.2023;[Epub] CrossRef
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease Ho Soo Chun, Minjong Lee, Hye Ah Lee, Seo Yeong Oh, Hyo Jeong Baek, Jae Won Moon, Yeon Jeong Kim, Jinha Lee, Hyoeun Kim, Hwi Young Kim, Kwon Yoo, Tae Hun Kim, Seung Up Kim Clinical Gastroenterology and Hepatology.2023; 21(2): 358. CrossRef
Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome Dong Hyun Sinn, Danbee Kang, Sung Chul Choi, Yun Soo Hong, Di Zhao, Eliseo Guallar, Yewan Park, Juhee Cho, Geum-Youn Gwak Clinical Gastroenterology and Hepatology.2023; 21(7): 1873. CrossRef
The association of non‐alcoholic fatty liver disease between parents and adolescent children Yewan Park, Dong Hyun Sinn, Kyunga Kim, Geum‐Youn Gwak Alimentary Pharmacology & Therapeutics.2023; 57(2): 245. CrossRef
Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim European Journal of Clinical Investigation.2023;[Epub] CrossRef
Reply Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak Clinical Gastroenterology and Hepatology.2023; 21(9): 2435. CrossRef
Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim Frontiers in Endocrinology.2023;[Epub] CrossRef
Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults Sun Young Shim, Sun Jae Jung, Seung Up Kim, Hyeon Chang Kim Clinical Hypertension.2023;[Epub] CrossRef
Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease” Won Sohn, Yong-Han Paik Clinical and Molecular Hepatology.2023; 29(1): 182. CrossRef
Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations” Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(1): 185. CrossRef
Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways” Seung Min Lee, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef
Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults” Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(1): 179. CrossRef
Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection Jungnam Lee, Jong-In Chang, Young-Joo Jin, Jeong-Hoon Lee, Ju Yeon Kim, Dong Hyun Sinn, Soon Sun Kim, Hyun Woong Lee, Sun Hong Yoo, Jung Hwan Yu, Jin-Woo Lee European Journal of Gastroenterology & Hepatology.2023; 35(4): 431. CrossRef
Comparison of Guidelines for the Screening, Diagnosis, and Noninvasive Assessment of Nonalcoholic Fatty Liver Disease Kenneth W. Chow, Pragyat Futela, Aryan Saharan, Sammy Saab Journal of Clinical and Experimental Hepatology.2023; 13(5): 783. CrossRef
Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease Min-Kyu Kang, Min-Cheol Kim Medicina.2023; 59(2): 375. CrossRef
The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review George Chen, Bubu Banini, Albert Do, Joseph K. Lim Clinical and Molecular Hepatology.2023; 29(Suppl): S319. CrossRef
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(Suppl): S220. CrossRef
Global incidence and prevalence of nonalcoholic fatty liver disease Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah Clinical and Molecular Hepatology.2023; 29(Suppl): S32. CrossRef
Non-alcoholic fatty liver disease: the pathologist’s perspective Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S302. CrossRef
Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models Dong Yun Kim, Kyu Sik Chung, Jun Yong Park, Heon Yung Gee Biomedicine & Pharmacotherapy.2023; 161: 114445. CrossRef
Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease Goh Eun Chung, Sohee Oh, Dong-Won Ahn, Su Hwan Kim, Yong Jin Jung, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, Ji Bong Jeong Scientific Reports.2023;[Epub] CrossRef
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef
Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification Hwi Young Kim, Da Jung Kim, Hye Ah Lee, Joo-Youn Cho, Won Kim Metabolites.2023; 13(3): 444. CrossRef
Nonalcoholic fatty liver disease and non-liver comorbidities Richie Manikat, Mindie H. Nguyen Clinical and Molecular Hepatology.2023; 29(Suppl): s86. CrossRef
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease Peter Konyn, Aijaz Ahmed, Donghee Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S43. CrossRef
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials Jihyun An, Joo Hyun Sohn Clinical and Molecular Hepatology.2023; 29(Suppl): S268. CrossRef
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(Suppl): S150. CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef
Comparison between obese and non-obese nonalcoholic fatty liver disease Wah-Kheong Chan Clinical and Molecular Hepatology.2023; 29(Suppl): S58. CrossRef
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future Jung Hwan Yu, Han Ah Lee, Seung Up Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S136. CrossRef
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease Georg Semmler, Christian Datz, Michael Trauner Clinical and Molecular Hepatology.2023; 29(Suppl): S244. CrossRef
Non-alcoholic fatty liver disease: Definition and subtypes Seul Ki Han, Soon Koo Baik, Moon Young Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S5. CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease Hyunwoo Oh, Won Sohn, Yong Kyun Cho Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis Yi-wen Shi, Jian-Gao Fan Clinical and Molecular Hepatology.2023; 29(Suppl): S228. CrossRef
Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management Anja Geerts, Sander Lefere Clinical and Molecular Hepatology.2023; 29(Suppl): S276. CrossRef
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra Clinical and Molecular Hepatology.2023; 29(Suppl): S286. CrossRef
CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease Ha Neul Kim, Hong Jae Jeon, Hei Gwon Choi, In Sun Kwon, Woo Sun Rou, Jeong Eun Lee, Tae Hee Lee, Seok Hyun Kim, Byung Seok Lee, Kyung Sook Shin, Hyun Jung Lee, Hyuk Soo Eun BMC Gastroenterology.2023;[Epub] CrossRef
How many times should we repeat measurements of the ultrasound-guided attenuation parameter for evaluating hepatic steatosis? Duck Min Seo, Sang Min Lee, Ji Won Park, Min-Jeong Kim, Hong Il Ha, Sun-Young Park, Kwanseop Lee Ultrasonography.2023; 42(2): 227. CrossRef
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review Young-Joo Jin Clinical and Molecular Hepatology.2023; 29(2): 414. CrossRef
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how? Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang Clinical and Molecular Hepatology.2023; 29(2): 404. CrossRef
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease Ji-Won Park, Ki Tae Suk Clinical and Molecular Hepatology.2023; 29(2): 408. CrossRef
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed Philipp Kasper, Münevver Demir, Hans-Michael Steffen Clinical and Molecular Hepatology.2023; 29(2): 390. CrossRef
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith Clinical and Molecular Hepatology.2023; 29(2): 433. CrossRef
The growing burden of non-alcoholic fatty liver disease on mortality Ju-Yeon Cho, Won Sohn Clinical and Molecular Hepatology.2023; 29(2): 374. CrossRef
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease Min Kyu Kang, Yu Rim Lee, Se Young Jang, Won Young Tak, Young Oh Kweon, Jeong Eun Song, Rohit Loomba, Soo Young Park, Jung Gil Park Hepatology International.2023; 17(3): 626. CrossRef
Genetic association study identifies genetic variants for non-alcoholic fatty liver without comorbidities in the Korean population Yeon Jun Kim, Yoon Shin Cho Genes & Genomics.2023; 45(7): 847. CrossRef
Association between the fatty liver index and the risk of fracture among individuals over the age of 50 years: a nationwide population-based study Goh Eun Chung, Eun Ju Cho, Min Joo Kim, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu Frontiers in Endocrinology.2023;[Epub] CrossRef
Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease Han Ah Lee, Hwi Young Kim International Journal of Molecular Sciences.2023; 24(11): 9324. CrossRef
Low‐quality muscle mass rather than normal‐quality muscle mass determines fibrosis progression in biopsy‐proven NAFLD Yun Kyu Lee, Bo Kyung Koo, Sae Kyung Joo, Dong Hyeon Lee, Heejoon Jang, Jee Won Chai, Myoung Seok Lee, Si Won Jang, Young Ho So, Jeong Hwan Park, Mee Soo Chang, Won Kim Alimentary Pharmacology & Therapeutics.2023; 58(3): 322. CrossRef
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef
Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang BMC Gastroenterology.2023;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik JHEP Reports.2023; 5(9): 100810. CrossRef
Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee Ultrasonography.2023; 42(3): 421. CrossRef
Serum resistin and the risk for hepatocellular carcinoma in diabetic patients Mona Mohamed Ibrahim Abdalla World Journal of Gastroenterology.2023; 29(27): 4271. CrossRef
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong Gut and Liver.2023; 17(4): 610. CrossRef
The correlation between NAFLD and serum uric acid to serum creatinine ratio Jangwon Choi, Hyun Joe, Jung-Eun Oh, Yong-Jin Cho, Hwang-Sik Shin, Nam Hun Heo, Gulali Aktas PLOS ONE.2023; 18(7): e0288666. CrossRef
Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non‐cirrhotic patients with chronic hepatitis B Cheol‐Hyung Lee, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon Alimentary Pharmacology & Therapeutics.2023; 58(7): 704. CrossRef
Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease Ho Soo Chun Gut and Liver.2023; 17(4): 485. CrossRef
KASL clinical practice guidelines for management of autoimmune hepatitis 2022
Clinical and Molecular Hepatology.2023; 29(3): 542. CrossRef
Comments on Relationship between the High Fatty Liver Index and Risk of Fracture: Reply Min-Ji Kim, Jae-Hyung Roh, Jae-Han Jeon Gut and Liver.2023; 17(4): 663. CrossRef
Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid PLOS ONE.2023; 18(7): e0288820. CrossRef
Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial Han Ah Lee, Hyeyoung Moon, Yuri Kim, Hye Ah Lee, Hwi Young Kim Trials.2023;[Epub] CrossRef
Associations of Serum Uric Acid Level With Liver Enzymes, Nonalcoholic Fatty Liver Disease, and Liver Fibrosis in Korean Men and Women: A Cross-Sectional Study Using Nationally Representative Data Jun Myong Lee, Hye Won Kim, So Young Heo, Kyung Yi Do, Jun Deok Lee, Seul Ki Han, Soon Koo Baik, Moon Young Kim, Sei-Jin Chang Journal of Korean Medical Science.2023;[Epub] CrossRef
Statins for treatment of fatty liver disease: Recent advances Xiao-Hui Fang, Cai-E Wang, Jiao Deng, Xing-Shun Qi World Chinese Journal of Digestology.2023; 31(16): 659. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
The effect of hepatic steatosis on 18F-FDG uptake in PET-CT examinations of cancer Egyptian patients Magdi A. Ali, Eman El-Abd, Mohamed Morsi, Mohamed M. El Safwany, Mohamed Z. El-Sayed European Journal of Hybrid Imaging.2023;[Epub] CrossRef
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity Gi-Ae Kim, Joon Ho Moon, Won Kim Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef
Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea Yuri Cho, SeongBeom Park, SeonYoung Park, WonJung Choi, Book Kim, Helin Han Infectious Diseases and Therapy.2023; 12(10): 2387. CrossRef
Association between waist circumference trajectories and incident non-alcoholic fatty liver disease Jun-Hyuk Lee, Soyoung Jeon, Hye Sun Lee, Yu-Jin Kwon Obesity Research & Clinical Practice.2023; 17(5): 398. CrossRef
Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention Tianyu Mao, Yiwen Sun, Xinyi Xu, Kang He Hepatology Communications.2023;[Epub] CrossRef
Approach to Fatty Liver Disease in Patients with Type 2 Diabetes Ji Cheol Bae The Journal of Korean Diabetes.2023; 24(3): 107. CrossRef
Lactobacillus plantarum ameliorates NASH-related inflammation by upregulating l-arginine production Dong Yun Kim, Jun Yong Park, Heon Yung Gee Experimental & Molecular Medicine.2023; 55(11): 2332. CrossRef
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera Hepatology.2023; 78(6): 1858. CrossRef
Association between total body muscle percentage and prevalence of non-alcoholic fatty liver disease in Korean adults findings from an 18-year follow-up: a prospective cohort study Byoung Chan Ahn, Chul Yong Park, Jung Hee Hong, Ki Ook Baek Journal of Yeungnam Medical Science.2023; 40(Suppl): S47. CrossRef
The Association of Perfluoroalkyl Substance Exposure and a Serum Liver Function Marker in Korean Adults Jisuk Yun, Soon-Chan Kwon Toxics.2023; 11(12): 965. CrossRef
Alcohol consumption and the risk of liver disease: a nationwide, population-based study Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Frontiers in Medicine.2023;[Epub] CrossRef
Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity T.S. Krolevets, M.I. Syrovenko, M.A. Livzan Russian Journal of Evidence-Based Gastroenterology.2023; 12(4): 43. CrossRef
Association of Hepatic Fat Deposition and Severity of Acanthosis Nigricans in Children and Adolescents with Obesity Junhyung Lee, Hye-ji An, Young-Gyun Seo, Hong Ji Song, Hye-Mi Noh, Yu-Jin Paek, Kyung Hee Park Korean Journal of Family Practice.2023; 13(4): 240. CrossRef
Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease Chan-Young Jung, Geun Woo Ryu, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Diabetologia.2022; 65(3): 518. CrossRef
Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study Seung Min Chung, Min Kyu Kang, Jinho Jung, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Rohit Loomba, Jung Gil Park, Jun Sung Moon Diabetes Research and Clinical Practice.2022; 184: 109208. CrossRef
Benefit of Antiviral Therapy for HBV-Related HCC with Undetectable HBV DNA Is Still Dubious Suprabhat Giri, Harish Darak, Sunil Kasturi Digestive Diseases and Sciences.2022; 67(10): 4962. CrossRef
Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role Haripriya Gupta, Byeong-Hyun Min, Raja Ganesan, Yoseph Asmelash Gebru, Satya Priya Sharma, Eunju Park, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Ji-Ye Hyun, Jung-A. Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Do Biomedicines.2022; 10(3): 550. CrossRef
Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis Heejoon Jang, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Joon Yeul Nam, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon Hepatology.2022; 76(2): 492. CrossRef
The Phase 2 Study to Evaluate Efficacy and Safety of Lanifibranor in Patients with Nonalcoholic Steatohepatitis: Back in the Spotlight? Sae Hwan Lee The Korean Journal of Gastroenterology.2022; 79(3): 138. CrossRef
Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study Chan-Young Jung, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim Diabetes & Metabolism.2022; 48(4): 101344. CrossRef
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, Jean-François Dufour International Journal of Molecular Sciences.2022; 23(8): 4305. CrossRef
Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae Clinical and Molecular Hepatology.2022; 28(2): 196. CrossRef
Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Youn Huh, Yoon Jeong Cho, Ga Eun Nam Journal of Obesity & Metabolic Syndrome.2022; 31(1): 17. CrossRef
Gamma‐glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non‐alcoholic fatty liver disease Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang Journal of Gastroenterology and Hepatology.2022; 37(8): 1624. CrossRef
The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu Frontiers in Oncology.2022;[Epub] CrossRef
Association of Low Skeletal Muscle Mass with the Phenotype of Lean Non-Alcoholic Fatty Liver Disease Jun-Hyeon Byeon, Min-Kyu Kang, Min-Cheol Kim Healthcare.2022; 10(5): 850. CrossRef
Association of Metabolomic Change and Treatment Response in Patients with Non-Alcoholic Fatty Liver Disease Kwang Seob Lee, Yongin Cho, Hongkyung Kim, Hyunkyeong Hwang, Jin Won Cho, Yong-ho Lee, Sang-Guk Lee Biomedicines.2022; 10(6): 1216. CrossRef
Risk of liver fibrosis in patients with prediabetes and diabetes mellitus Jongsin Park, Heon-Ju Kwon, Won Sohn, Ju-Yeon Cho, Soo Jin Park, Yoosoo Chang, Seungho Ryu, Byung Ik Kim, Yong Kyun Cho, Chen-Hua Liu PLOS ONE.2022; 17(6): e0269070. CrossRef
Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study Chan-Young Jung, Ho Soo Chun, Minjong Lee, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim Diabetes & Metabolism.2022; 48(5): 101362. CrossRef
Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Mira Kang, Eliseo Guallar, Yun Soo Hong, Kyung Hyun Lee, Jiyeon Park, Juhee Cho, Geum‐Youn Gwak Hepatology.2022; 76(6): 1746. CrossRef
Short-term outcome of bariatric surgery on nonalcoholic fatty liver disease: a Korean perspective Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo Annals of Surgical Treatment and Research.2022; 102(6): 353. CrossRef
A Case Report of Nonalcoholic Fatty Liver Disease with Obesity and Dyslipidemia Eujin Kim, Cho-Hyun Hwang, Juyoung Lee, Eungyeong Jang, Youngchul Kim, Jang-Hoon Lee The Journal of Internal Korean Medicine.2022; 43(2): 184. CrossRef
Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study Wenting Wang, Jianping Ren, Wenzhao Zhou, Jinyu Huang, Guomin Wu, Fenfang Yang, Shuang Yuan, Juan Fang, Jing Liu, Yao Jin, Haiyang Qi, Yuyang Miao, Yanna Le, Cenhong Ge, Xiantao Qiu, JinJing Wang, Ping Huang, Zixin Liu, Sheng Wang Scientific Reports.2022;[Epub] CrossRef
Obstructive Sleep Apnea and Nonalcoholic Fatty Liver Disease in the General Population: A Cross-Sectional Study Using Nationally Representative Data Taeyun Kim, Hyunji Choi, Jaejun Lee, Jehun Kim International Journal of Environmental Research and Public Health.2022; 19(14): 8398. CrossRef
Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions Jung Il Lee Gut and Liver.2022; 16(4): 497. CrossRef
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim Clinical and Molecular Hepatology.2022; 28(3): 425. CrossRef
Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database Hankil Lee, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2022; 37(11): 2154. CrossRef
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N Journal of Hepatology.2022; 77(6): 1482. CrossRef
Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim Abdominal Radiology.2022; 47(11): 3733. CrossRef
Fatty Liver Change in Korean Adults in a Systematic Social Distancing System Amid the COVID-19 Pandemic: A Multicenter Analysis Ji-Hee Haam, Yang-Im Hur, Young-Sang Kim, Kyoung-Kon Kim, Jee-Hyun Kang, Hae-Jin Ko, Yoon Jeong Cho, Hye-In Choi, Kyu Rae Lee, Jung Ha Park, Soo Hyun Cho, Jong-Koo Kim, Taesic Lee, Myung-Jae Seo, Yeong Sook Yoon, Yoobin Seo, Ga Eun Nam, Sun Hyun Kim International Journal of Environmental Research and Public Health.2022; 19(16): 10444. CrossRef
Association between grip strength and non-alcoholic fatty liver disease: A systematic review and meta-analysis Liu Han, Shifeng Fu, Jianglei Li, Deliang Liu, Yuyong Tan Frontiers in Medicine.2022;[Epub] CrossRef
Correlation between shift work and non-alcoholic fatty liver disease among male workers in the steel manufacturing company of Korea: a cross-sectional study Kiseok Kim, Yong-Jin Lee, Soon-Chan Kwon, Young-Sun Min, Hyun Kyo Lee, Gwangin Baek, Sang Hyeon Kim, Eun-Chul Jang Annals of Occupational and Environmental Medicine.2022;[Epub] CrossRef
Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease Ki Choon Sim, Min Ju Kim, Yongwon Cho, Hyun Jin Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Yeo Eun Han, Tae Hyung Kim, Yoo Jin Lee Journal of Korean Medical Science.2022;[Epub] CrossRef
Bioelectrical Impedance Analysis Can Be an Effective Tool for Screening Fatty Liver in Patients with Suspected Liver Disease Jin Wook Choi, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Healthcare.2022; 10(11): 2268. CrossRef
Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes Pu Reun Roh, Sung Min Kim, Byung-Yoon Kang, Kyoung Do Mun, Jong Geun Park, Min Woo Kang, Wonhee Hur, Ji Won Han, Heechul Nam, Seung Kew Yoon, Pil Soo Sung Biomedicine & Pharmacotherapy.2022; 156: 113952. CrossRef
Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis Sangsoo Han, Miyoung Choi, Bora Lee, Hye-Won Lee, Seong Hee Kang, Yuri Cho, Sang Bong Ahn, Do Seon Song, Dae Won Jun, Jieun Lee, Jeong-Ju Yoo Gut and Liver.2022; 16(6): 952. CrossRef
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2022; 28(4): 814. CrossRef
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations Soon Sun Kim, Jae Youn Cheong Clinical and Molecular Hepatology.2022; 28(4): 802. CrossRef
Association between small dense LDL levels and hepatic fibrosis in patients with nonalcoholic fatty liver disease Sun Young Kim, Subin Mun, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Sang-Heon Cho, Jin-Woo Lee Medicine.2022; 101(37): e30527. CrossRef
A Review of Research Trends in Traditional Korean Medicine for Nonalcoholic Fatty Liver Disease Na-yeon Kim, Mi-jung Yoon, Hong-sik Choi, Seung-mo Kim, Sang-chan Kim, Kyung-soon Kim The Journal of Internal Korean Medicine.2022; 43(4): 680. CrossRef
Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2022; 28(4): 933. CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy Pengyu Yao, Yajuan Liu Molecules.2022; 28(1): 272. CrossRef
The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review Elena S. George, Surbhi Sood, Nicole Kiss, Robin M. Daly, Amanda J. Nicoll, Stuart K. Roberts, Brenton J. Baguley Current Oncology.2022; 30(1): 48. CrossRef
Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Korean Patients Undergoing Bariatric Surgery Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo Journal of Metabolic and Bariatric Surgery.2022; 11(2): 63. CrossRef
Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population Eun-Ju Cho, Gu-Cheol Jung, Min-Sun Kwak, Jong-In Yang, Jeong-Yoon Yim, Su-Jong Yu, Goh-Eun Chung Diagnostics.2021; 11(12): 2233. CrossRef
Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus Kiyoung Lim, Minkyu Kang, Junggil Park Nutrients.2021; 13(10): 3400. CrossRef
Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression Jeong-An Gim, Soo Min Bang, Young-Sun Lee, Yoonseok Lee, Sun Young Yim, Young Kul Jung, Hayeon Kim, Baek-Hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun, Matias A. Avila PLOS ONE.2021; 16(8): e0255822. CrossRef
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li Frontiers in Endocrinology.2021;[Epub] CrossRef
Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial Won Myung Lee, Jea Hurn Bae, Young Chang, Sae Hwan Lee, Ji Eun Moon, Soung Won Jeong, Jae Young Jang, Sang Gyune Kim, Hong Soo Kim, Jeong-Ju Yoo, Young Seok Kim Nutrients.2021; 13(12): 4453. CrossRef
Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease Jae Seung Lee, Dong Hyun Sinn, Soo Young Park, Hye Jung Shin, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Joo Hyun Oh, Jung Il Lee, Seung Up Kim Cancers.2021; 13(18): 4567. CrossRef
There is some dissatisfaction with the term “nonalcoholic fatty liver disease (NAFLD),” which overemphasizes alcohol and underemphasizes the importance of metabolic risk factors in this disease. Recently, a consensus recommended “metabolic (dysfunction)-associated fatty liver disease (MAFLD)” as a more appropriate term to describe fatty liver diseases (FLD) associated with metabolic dysfunction. During the definition change from NAFLD to MAFLD, subjects with FLD and metabolic abnormalities, together with other etiologies of liver diseases such as alcohol, virus, or medication who have been excluded from the NAFLD criteria, were added to the MAFLD criteria, while subjects with FLD but without metabolic abnormality, who have been included in the NAFLD criteria, were excluded from the MAFLD criteria. This means that there is an emphasis on the metabolic dysfunction in MAFLD which may underestimate the prognostic value of hepatic steatosis itself, whereas the MAFLD criteria might better identify subjects who are at a higher risk of hepatic or cardiovascular outcomes. However, non-metabolic risk NAFLD subjects who are excluded from the MAFLD criteria are missed from the diagnosis, and their potential risk can be the cause of future diseases. Although huge controversies remain, this review focused on summarizing recent studies that compared the clinical and prognostic characteristics between subjects with NAFLD and MAFLD.
Citations
Citations to this article as recorded by
Research Progress of the Relationship between Metabolic-Associated Fatty Liver Disease and Colorectal Neoplasia 杨 包 Advances in Clinical Medicine.2025; 15(02): 1996. CrossRef
Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges Dario Piatto, Delia De Biasio, Francesco Giustino Cesaro, Gianmario Forcina, Vittoria Frattolillo, Antonio Colucci, Fabio Lamberti, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Journal of Clinical Medicine.2025; 14(11): 3911. CrossRef
The utility of an artificial intelligence model based on decision tree and evolution algorithm to evaluate steatotic liver disease in a primary care setting A.C. Goulart, A.P. Alencar, G. Tunes, L.L.T. Bianchi, M.H. Miname, C.M. Padilha, J.M.S. Pescuma, A.L.C.C. Rodrigues, B.B. Henares, M.S. de Almeida, T.A.O. Machado, D.H. Syllos, Y.P. Wang, M. Rienzo Brazilian Journal of Medical and Biological Research.2025;[Epub] CrossRef
Prevalence and risk factors of metabolic associated fatty liver disease in lean patients with bipolar disorder: a retrospective cross-sectional study Weihong Lei, Jiahuan Li, Yiyi Liu, Ying Wang, Qing Wu Frontiers in Endocrinology.2025;[Epub] CrossRef
Tracking Mutual Interactions of Mitochondria/Lysosomes/Lipid Droplets in DILI and NAFLD with a Viscosity and Peroxynitrite-Sensitive Single Fluorescent Probe Chunhua Fan, Xionghao Xu, Bo Zhao, Tao Jiang, Tianxin Liu, Chaewoon Cho, Juyoung Yoon, Zhengliang Lu Analytical Chemistry.2025; 97(40): 21935. CrossRef
Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes Tulio L Correa, Nikki Duong World Journal of Hepatology.2025;[Epub] CrossRef
Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink Cornelius J. Fernandez, Mohammed Alkhalifah, Hafsa Afsar, Joseph M. Pappachan Pathogens.2024; 13(1): 68. CrossRef
High prevalence of fatty liver and its association with metabolic syndrome among rural adults with chronic hepatitis C: Implications for primary healthcare Ta-Jen Wang, Mei-Yen Chen, Yu-Chih Lin, Wen-Nan Chiu, Tung-Jung Huang, Hsu-Huei Weng BMC Public Health.2024;[Epub] CrossRef
Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population Young Lee, Eun Ju Cho, Eun Kyung Choe, Min-Sun Kwak, Jong In Yang, Seung-Won Oh, Jeong Yoon Yim, Goh Eun Chung Scientific Reports.2024;[Epub] CrossRef
Prevalence of NAFLD, MAFLD, and MASLD: NHANES 1999-2018 Jie Pan, Feilong Wu, Mingtao Chen, Jinsen He, Yingying Gu, Lei Pei, Xuye Lai, Zhenfeng Zhang, Lili Yang Diabetes & Metabolism.2024; 50(6): 101562. CrossRef
Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification Min Kyu Kang, Jeong Eun Song, Rohit Loomba, Soo Young Park, Won Young Tak, Young Oh Kweon, Yu Rim Lee, Jung Gil Park Scientific Reports.2024;[Epub] CrossRef
Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Min Kyu Kang, Jeung Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Yu Rim Lee, Jung Gil Park Diagnostics.2024; 14(20): 2305. CrossRef
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Michael D. Shapiro, Li-Li Chen, Ming-Hua Zheng Cardiology Plus.2024; 9(4): 275. CrossRef
Does metabolic dysfunction-associated fatty liver disease increase the risk of chronic kidney disease? A meta-analysis of cohort studies Wanghao Liu, Xiaoying Sun BMC Nephrology.2024;[Epub] CrossRef
Leukocyte telomere length decreased the risk of mortality in patients with alcohol-associated liver disease Jiahong Yi, Hui Guo, Chang Jiang, Junyi Duan, Ju Xue, Yue Zhao, Wenzhuo He, Liangping Xia Frontiers in Endocrinology.2024;[Epub] CrossRef
Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome Dong Hyun Sinn, Danbee Kang, Sung Chul Choi, Yun Soo Hong, Di Zhao, Eliseo Guallar, Yewan Park, Juhee Cho, Geum-Youn Gwak Clinical Gastroenterology and Hepatology.2023; 21(7): 1873. CrossRef
Non-alcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology Camila Cristiane Pansa, Letícia Ramos Molica, Karen C. M. Moraes Scandinavian Journal of Gastroenterology.2023; 58(5): 521. CrossRef
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim American Journal of Gastroenterology.2023; 118(6): 1001. CrossRef
Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim European Journal of Clinical Investigation.2023;[Epub] CrossRef
Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease Goh Eun Chung, Su Jong Yu, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Dong Wook Shin, Donghee Kim, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho BMC Medicine.2023;[Epub] CrossRef
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim Liver International.2023; 43(3): 608. CrossRef
The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review George Chen, Bubu Banini, Albert Do, Joseph K. Lim Clinical and Molecular Hepatology.2023; 29(Suppl): S319. CrossRef
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(Suppl): S220. CrossRef
Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria Jie Pan, Yijie Ding, Yan Sun, Qiuyan Li, Tianyi Wei, Yingying Gu, Yujia Zhou, Nengzhi Pang, Lei Pei, Sixi Ma, Mengqi Gao, Ying Xiao, De Hu, Feilong Wu, Lili Yang Journal of Clinical Medicine.2023; 12(6): 2126. CrossRef
Chinese Visceral Adipose Index Shows Superior Diagnostic Performance in Predicting the Risk of Metabolic Dysfunction Associated Fatty Liver Disease in Early Postmenopausal Chinese Women Yayun Lu, Lingxia Ge, Hao Yang, Yufeng He, Yujun Wang Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 607. CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef
Non-alcoholic fatty liver disease: Definition and subtypes Seul Ki Han, Soon Koo Baik, Moon Young Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S5. CrossRef
MAFLD: How is it different from NAFLD? Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George Clinical and Molecular Hepatology.2023; 29(Suppl): S17. CrossRef
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives Shang-Chin Huang, Chun-Jen Liu Clinical and Molecular Hepatology.2023; 29(2): 320. CrossRef
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease Min Kyu Kang, Yu Rim Lee, Se Young Jang, Won Young Tak, Young Oh Kweon, Jeong Eun Song, Rohit Loomba, Soo Young Park, Jung Gil Park Hepatology International.2023; 17(3): 626. CrossRef
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis Bryan Tan, Xin-Hui Pan, Han Shi Jocelyn Chew, Rachel Sze Jen Goh, Chaoxing Lin, Vickram Vijay Anand, Ethan Cheng Zhe Lee, Kai En Chan, Gwyneth Kong, Christen En Ya Ong, Hui Charlotte Chung, Dan Yock Young, Mark Y. Chan, Chin Meng Khoo, Anurag Mehta, Mark International Journal of Obesity.2023; 47(8): 677. CrossRef
Differential risk of 23 site‐specific incident cancers and cancer‐related mortality among patients with metabolic dysfunction‐associated fatty liver disease: a population‐based cohort study with 9.7 million Korean subjects Goh Eun Chung, Su Jong Yu, Jeong‐Ju Yoo, Yuri Cho, Kyu‐na Lee, Dong Wook Shin, Yoon Jun Kim, Jung‐Hwan Yoon, Kyungdo Han, Eun Ju Cho Cancer Communications.2023; 43(8): 863. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik JHEP Reports.2023; 5(9): 100810. CrossRef
Nonalcoholic fatty liver disease without overlapping metabolic‐associated fatty liver disease and the risk of incident type 2 diabetes Yoosun Cho, Yoosoo Chang, Seungho Ryu, Sarah H. Wild, Christopher D. Byrne Liver International.2023; 43(11): 2445. CrossRef
The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef
Metabolic dysfunction: The silenced connection with fatty liver disease Mariana M. Ramírez-Mejía, Xingshun Qi, Ludovico Abenavoli, Manuel Romero-Gómez, Mohammed Eslam, Nahum Méndez-Sánchez Annals of Hepatology.2023; 28(6): 101138. CrossRef
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong Gut and Liver.2023; 17(4): 610. CrossRef
Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Xuehong Zhang, Sang Hoon Ahn International Journal of Cancer.2023; 153(8): 1448. CrossRef
Coagulation Dysfunctions in Non-Alcoholic Fatty Liver Disease—Oxidative Stress and Inflammation Relevance Madalina Andreea Robea, Ioana-Miruna Balmus, Irina Girleanu, Laura Huiban, Cristina Muzica, Alin Ciobica, Carol Stanciu, Carmen Diana Cimpoesu, Anca Trifan Medicina.2023; 59(9): 1614. CrossRef
From Nonalcoholic Steatohepatits to Steatotic Liver Disease: A Long Way Helma Cotrim Diagnostics.2023; 13(19): 3104. CrossRef
Impact of
Porphyromonas gingivalis
-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
Linbo Liu, Yan Geng, Chaoliang Xiong Annals of Medicine.2023;[Epub] CrossRef
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity Gi-Ae Kim, Joon Ho Moon, Won Kim Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef
Correlation between serum uric acid and body fat distribution in patients with MAFLD Min Tao, Jing Liu, Xingyu Chen, Qing Wang, Miao He, Wenwen Chen, Cong Wang, Lili Zhang BMC Endocrine Disorders.2023;[Epub] CrossRef
Increased detection rates of advanced colorectal adenoma in women with metabolic dysfunction-associated fatty liver disease Yan Gong, Juan Kang, Xinyan Wang, Yansong Zheng, Ying Sui, Wenping Lu Heliyon.2023; 9(11): e22391. CrossRef
Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma Sang Hyun Seo, Kyung Joo Cho, Hye Jung Park, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Hee Cheon, Jong In Yook, Man-Deuk Kim, Dong Jin Joo, Seung Up Kim Cell Communication and Signaling.2023;[Epub] CrossRef
The relationship between skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease subtypes in middle-aged and elderly population: a single-center retrospective study Mengchen Xing, Yanlan Ni, Ye Zhang, Xiaoqian Zhao, Xin Yu Frontiers in Nutrition.2023;[Epub] CrossRef
The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD Zifeng Yang, Juan Yang, Jingjing Cai, Xiao-Jing Zhang, Peng Zhang, Zhi-Gang She, Hongliang Li Reviews in Cardiovascular Medicine.2023;[Epub] CrossRef
Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia Yohwan Lim, Seogsong Jeong, Myunghee Hong, Hyun Wook Han Reviews in Cardiovascular Medicine.2023;[Epub] CrossRef
Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim Cancers.2022; 14(20): 5002. CrossRef
Nonalcoholic Fatty Liver Disease Is a Precursor of New-Onset Metabolic Syndrome in Metabolically Healthy Young Adults Jeong-Ju Yoo, Eun Ju Cho, Goh Eun Chung, Young Chang, Yuri Cho, Sang-Hyun Park, Su-Min Jeong, Bo-Yeon Kim, Dong Wook Shin, Yun Joon Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu Journal of Clinical Medicine.2022; 11(4): 935. CrossRef
Non-alcoholic/Metabolic-Associated Fatty Liver Disease and Helicobacter pylori Additively Increase the Risk of Arterial Stiffness Ji Min Choi, Hyo Eun Park, Yoo Min Han, Jooyoung Lee, Heesun Lee, Su Jin Chung, Seon Hee Lim, Jeong Yoon Yim, Goh Eun Chung Frontiers in Medicine.2022;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study Chan-Young Jung, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim Diabetes & Metabolism.2022; 48(4): 101344. CrossRef
Empirically-Derived Dietary Patterns in Relation to Non-Alcoholic Fatty Liver Diseases Among Adult Participants in Amol, Northern Iran: A Structural Equation Modeling Approach Azam Doustmohammadian, Elham Pishgar, Cain C. T. Clark, Elham Sobhrakhshankhah, Mehdi Nikkhah, Amir Hossein Faraji, Nima Motamed, Mohsen Reza Mansourian, Bahareh Amirkalali, Mansooreh Maadi, Maryam Sadat Kasaii, Hamidreza Ebrahimi, Farhad Zamani Frontiers in Nutrition.2022;[Epub] CrossRef
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef
The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu Frontiers in Oncology.2022;[Epub] CrossRef
Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics Simona Riccio, Rosa Melone, Caterina Vitulano, Pierfrancesco Guida, Ivan Maddaluno, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa World Journal of Clinical Pediatrics.2022; 11(3): 221. CrossRef
MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups Hyoeun Kim, Chan Joo Lee, Sang Hoon Ahn, Kwan Sik Lee, Byoung Kwon Lee, Su Jung Baik, Seung Up Kim, Jung Il Lee Digestive Diseases and Sciences.2022; 67(10): 4919. CrossRef
From NAFLD to MAFLD: Not just a change in the name Jing Zeng, Jian-Gao Fan Hepatobiliary & Pancreatic Diseases International.2022; 21(6): 511. CrossRef
I148M variant of PNPLA3-gene is not associated with metabolic syndrome in patients with NAFLD in the Indian ethnicity Govardhan Bale, Sasikala Mitnala, Nagaraja Rao Padaki, Mithun Sharma, Anand V. Kulkarni, Smita C. Pawar, Nageshwar Reddy D, Ravikanth Vishnubhotla Human Gene.2022; 33: 201073. CrossRef
Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions Francesca Lanzaro, Stefano Guarino, Elisabetta D'Addio, Alessandra Salvatori, Josè Alberto D'Anna, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa World Journal of Hepatology.2022; 14(6): 1087. CrossRef
Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, Jooyoung Chang, Sung Min Kim, Joung Sik Son, Gyeongsil Lee, Won Kim, Sang Min Park Gut and Liver.2022; 16(4): 589. CrossRef
New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai Life.2022; 12(8): 1189. CrossRef
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim Hepatology Research.2022; 52(12): 975. CrossRef
Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai Biomedicines.2022; 10(10): 2375. CrossRef
Non-alcoholic fatty liver disease: a global concern Gerri Mortimore Practice Nursing.2022; 33(9): 358. CrossRef
Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study Dina Attia, Shereen Abdel Alem, Wafaa El‐Akel, Wael Abdel‐Razek, Mohamed Eslam, Yasser Fouad, Imam Waked Alimentary Pharmacology & Therapeutics.2022; 56(11-12): 1581. CrossRef
Comparison of non-invasive imaging methods and laboratory findings on non-alcoholic fatty liver disease (NAFLD) in childhood Caner DOĞAN, Meryem KEÇELİ BAŞARAN, Okan GÜRKAN, Seda GÜLEÇ GEYLANİ Journal of Health Sciences and Medicine.2022; 5(6): 1541. CrossRef
Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem Sébastien Le Garf, Véronique Nègre, Rodolphe Anty, Philippe Gual Biomedicines.2021; 9(12): 1915. CrossRef
The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease Ji-Yeon Seo, Jung-Ho Bae, Min-Sun Kwak, Jong-In Yang, Su-Jin Chung, Jeong-Yoon Yim, Seon-Hee Lim, Goh-Eun Chung Biomedicines.2021; 9(10): 1401. CrossRef
Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease Hee Kyung Shin, Jeong Hwan Park, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Jin-Woo Lee, Won Kim Scientific Reports.2021;[Epub] CrossRef
Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease Ho Soo Chun, Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Cachexia, Sarcopenia and Muscle.2021; 12(5): 1168. CrossRef
Diabetes and metabolic dysfunction-associated fatty liver disease Timothy M.E. Davis Metabolism.2021; 123: 154868. CrossRef
Functions of two distinct Kupffer cells in the liver Chunye Zhang, Shuai Liu, Ming Yang Exploration of Medicine.2021; : 511. CrossRef
The Change in Metabolic Syndrome Status and the Risk of Nonviral Liver Cirrhosis Goh-Eun Chung, Young Chang, Yuri Cho, Eun-Ju Cho, Jeong-Ju Yoo, Sang-Hyun Park, Kyungdo Han, Dong-Wook Shin, Su-Jong Yu, Yoon-Jun Kim, Jung-Hwan Yoon Biomedicines.2021; 9(12): 1948. CrossRef
The nucleoside analog 4′-fluorouridine suppresses the replication of multiple enteroviruses by targeting 3D polymerase Yongkang Chen, Xiaohong Li, Fengyang Han, Beihong Ji, Yuan Li, Jingjing Yan, Min Wang, Jun Fan, Shuye Zhang, Lu Lu, Peng Zou, Miguel Angel Martinez Antimicrobial Agents and Chemotherapy.2024;[Epub] CrossRef
Genomic and computational-aided integrative drug repositioning strategy for EGFR and ROS1 mutated NSCLC Varsha Tripathi, Aishwarya Khare, Divyanshi Shukla, Shiv Bharadwaj, Nikhil Kirtipal, Vandana Ranjan International Immunopharmacology.2024; 139: 112682. CrossRef
Saffron extract attenuates Sofosbuvir‐induced retinal neurodegeneration in albino rat Walaa S. Elseady, Walaa A. Keshk, Walaa A. Negm, Walaa Elkhalawany, Hend Elhanafy, Marwa A.A. Ibrahim, Doaa A. Radwan The Anatomical Record.2023; 306(2): 422. CrossRef
Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease Mohammad El-Sayed, Magdy Elserafy, Maissa El Raziky, Wafaa Elakel, Yasmin Saad, Tarek Fayad, Mohamed Korany, Mai Mehrez, Rabab Salama, Maged Mahrous, Ayman Zaki, Mohamed Hassany, Islam Ammar, Kadry Elsaeed, Yehia Elshazly, Wahid Doss Arab Journal of Gastroenterology.2023; 24(1): 29. CrossRef
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan Ching-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, Kuo-Chih Tseng, Chi-Yi Chen, Hsing-Tao Kuo, Yi-Hsiang Huang, Chi-Ming Tai, Cheng-Yuan Peng, Ming-Jong Bair, Chien-Hung Chen, Ming-Lun Yeh, Chih-Lang Lin, Chun-Yen Lin, Pei-Lun Lee, Lee-Won Chong, Chao-Hung Hu Journal of the Formosan Medical Association.2022; 121(8): 1567. CrossRef
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo The Korean Journal of Internal Medicine.2022; 37(6): 1167. CrossRef
Se Ri Ryu, Jeong-Ju Yoo, Seong Hee Kang, Soung Won Jeong, Moon Young Kim, Young Kyu Cho, Young Chang, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Soon Koo Baik, Yong Jae Kim, Su Yeon Park, Baigal Baymbajav
Clin Mol Hepatol 2021;27(1):197-206. Published online December 3, 2020
Background/Aims The hepatic venous pressure gradient (HVPG) reflects portal hypertension, but its measurement is invasive. Transient elastography (TE) is a noninvasive method for evaluating liver stiffness (LS). We investigated the correlation between the value of LS, LS to platelet ratio (LPR), LS-spleen diameter-to-platelet ratio score (LSPS) and HVPG according to the etiology of cirrhosis, especially focused on alcoholic cirrhosis.
Methods Between January 2008 and March 2017, 556 patients who underwent HVPG and TE were consecutively enrolled. We evaluated LS, LPR, and LSPS according to the etiology of cirrhosis and analyzed their correlations with HVPG.
Results The LS value was higher in patients with alcoholic cirrhosis than viral cirrhosis based on the HVPG (43.5 vs. 32.0 kPa, P<0.001). There were no significant differences in the LPR or LSPS between alcoholic and viral cirrhosis groups, and the areas under the curves for the LPR and LSPS in subgroups according to HVPG levels were not superior to that for LS. In alcoholic cirrhosis, the LS cutoff value for predicting an HVPG ≥10 mmHg was 32.2 kPa with positive predictive value (PPV) of 94.5% and 36.6 kPa for HVPG ≥12 mmHg with PPV of 91.0%.
Conclusions The LS cutoff value should be determined separately for patients with alcoholic and viral cirrhosis. In alcoholic cirrhosis, the LS cutoff values were 32.2 and 36.6 kPa for predicting an HVPG ≥10 and ≥12 mmHg, respectively. However, there were no significant differences in the LPR or LSPS between alcoholic and viral cirrhosis groups.
Citations
Citations to this article as recorded by
Assessment of liver stiffness measurement-related markers in predicting liver-related events in viral cirrhosis with clinically significant portal hypertension Yan-Qiu Li, Yong-Qi Li, Jin-Ze Li, Bing-Bing Zhu, Yu Lu, Ying Feng, Xian-Bo Wang World Journal of Hepatology.2025;[Epub] CrossRef
Effect of tenofovir alafenamide on immune function and long-term prognosis in patients with chronic hepatitis B-related liver cirrhosis using two-dimensional ultrasound evaluation Yueran Wu, Xia Li, Xiaopeng Yang, Lijun Lin, Biying Zou, Yulin Chen Journal of Radiation Research and Applied Sciences.2025; 18(4): 102041. CrossRef
Analysis of Factors Influencing Prognosis and Assessment of 60 Cases of Decompensated Cirrhotic Patients with Portal Hypertension Xue Li, Shi Liu, Jin Li, Ning Liu, Hui Li, An Ge, Liang Wang, Xie Dong, Hui Wang, Ju Liu, Lin Zhang, Hao Dong Zhang, Wei Gou International Journal of General Medicine.2024; Volume 17: 1493. CrossRef
Enhancing liver cirrhosis varices and CSPH risk prediction with spleen stiffness measurement using 100-Hz probe Jeong-Ju Yoo, Sun Ah Maeng, Young Chang, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Gab Jin Cheon, Young Seok Kim, Hong Soo Kim, Sang Gyune Kim Scientific Reports.2024;[Epub] CrossRef
Non-invasive tests-based risk stratification: Baveno VII and beyond Georg Semmler, Mathias Jachs, Mattias Mandorfer Clinical and Molecular Hepatology.2023; 29(1): 105. CrossRef
The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus Jeong-Ju Yoo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(1): 102. CrossRef
Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus‐related liver cirrhosis David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Nikolaos Pyrsopoulos, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(8): 1372. CrossRef
Validation of non‐invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik, Dong Hyun Sinn Liver International.2023; 43(9): 1966. CrossRef
Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis Seunghwan Shin, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Diagnostics.2022; 12(2): 441. CrossRef
Diagnostic accuracy of transient elastography in diagnosing clinically significant portal hypertension in patients with chronic liver disease: a systematic review and meta-analysis Ashish Kumar, Hitoshi Maruyama, Anil Arora, Praveen Sharma, Shrihari Anil Anikhindi, Naresh Bansal, Mandhir Kumar, Piyush Ranjan, Munish Sachdeva, Shivam Khare Journal of Medical Ultrasonics.2022; 49(3): 333. CrossRef
Influence of portal vein occlusion on portal flow and liver elasticity in an animal model Simon Chatelin, Raoul Pop, Céline Giraudeau, Khalid Ambarki, Ning Jin, François Séverac, Elodie Breton, Jonathan Vappou NMR in Biomedicine.2021;[Epub] CrossRef
The Diagnostic Accuracy of LOGIQ S8 and E9 Shear Wave Elastography for Staging Hepatic Fibrosis, in Comparison with Transient Elastography Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Diagnostics.2021; 11(10): 1817. CrossRef
Tae Suk Kim, Ji Hoon Kim, Baek hui Kim, Young-Sun Lee, Yang Jae Yoo, Seong Hee Kang, Sang-June Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
Clin Mol Hepatol 2017;23(4):340-346. Published online June 20, 2017
Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 patients have achieved a complete response (CR) in advanced HCC. However, only four of these reports can be regarded as real CRs involving adequate assessments including imaging, serum tumor markers, and histologic examinations of completely resected specimens. A 54-year-old man with hepatitis C virus (HCV)-related liver cirrhosis (LC) presented to our unit. A CT scan demonstrated a 3.8-cm arterial hypervascular/portal-washout mass in the right lobe and invasion in the right portal vein. Twelve weeks after beginning sorafenib therapy, the AFP level was normalized and a CT scan showed a prominent decrease in the hepatic mass and a significant decrease in the volume of portal vein thrombosis (PVT). The patient received a right liver hemihepatectomy after 12 months. No viable tumor cells were found in the resected specimen, and there was no thrombotic obstruction of the portal vein. Twelve months later the patient showed no clinical evidence of HCC recurrence. This is the first case of CR in HCC treatment following sorafenib with histologically confirmed HCVrelated HCC without LC evidence, HCC with PVT, and a follow-up of longer than 12 months. This case seems to be an extremely unusual clinical outcome in advanced HCC.
Citations
Citations to this article as recorded by
The novel predictive nomograms for early death in metastatic hepatocellular carcinoma: A large cohort study Yue Wang, Long Ge, Yan Cai Medicine.2024; 103(1): e36812. CrossRef
Liver resection and transplantation in the era of checkpoint inhibitors Parissa Tabrizian, Rebecca Marino, Pierce K.H. Chow JHEP Reports.2024; 6(11): 101181. CrossRef
Sorafenib as first-line treatment for patients with primary hepatocellular carcinoma: an outcome evaluation Dung Thi Nguyen, Duong Hoang Nguyen, Van Thi Hong Nguyen Journal of International Medical Research.2023;[Epub] CrossRef
Automatic prediction of hepatic arterial infusion chemotherapy response in advanced hepatocellular carcinoma with deep learning radiomic nomogram Ziming Xu, Chao An, Feng Shi, He Ren, Yuze Li, Song Chen, Jiaqi Dou, Yajie Wang, Shaozhen Yan, Jie Lu, Huijun Chen European Radiology.2023; 33(12): 9038. CrossRef
Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors Junichi Arita, Akihiko Ichida, Rihito Nagata, Yuichiro Mihara, Yoshikuni Kawaguchi, Takeaki Ishizawa, Nobuhisa Akamatsu, Junichi Kaneko, Kiyoshi Hasegawa Journal of Hepato-Biliary-Pancreatic Sciences.2022; 29(7): 732. CrossRef
Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma Kuo-Wei Huang, Pei-Chang Lee, Yee Chao, Chien-Wei Su, I-Cheng Lee, Keng-Hsin Lan, Chi-Jen Chu, Yi-Ping Hung, San-Chi Chen, Ming-Chih Hou, Yi-Hsiang Huang Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
A Practical Nomogram and Risk Stratification System Predicting the Cancer-Specific Survival for Patients With Advanced Hepatocellular Carcinoma Dashuai Yang, Yang Su, Fangrui Zhao, Chen Chen, Kailiang Zhao, Xiangyun Xiong, Youming Ding Frontiers in Oncology.2022;[Epub] CrossRef
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma Soojin Kim, Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim, Seung Up Kim Journal of Gastroenterology and Hepatology.2021; 36(5): 1317. CrossRef
Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma Yoh Asahi, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Takeshi Aiyama, Yuzuru Sakamoto, Hirofumi Kamachi, Akinobu Taketomi World Journal of Gastrointestinal Surgery.2021; 13(10): 1245. CrossRef
Complete Pathological Response of Hepatocellular Carcinoma with Portal Vein Thrombosis Treated with Sorafenib—Report of a Case— Tetsushi MIZUTANI, Mizuo HASHIMOTO, Hiroaki USUI, Tomoki KOBAYASHI, Motonobu NISHIMURA, Kenji SAKAGUCHI Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2021; 82(3): 635. CrossRef
Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib Piero Colombatto, Coskun Ozer Demirtas, Gabriele Ricco, Luigi Civitano, Piero Boraschi, Paola Scalise, Daniela Cavallone, Filippo Oliveri, Veronica Romagnoli, Patrizia Bleve, Barbara Coco, Antonio Salvati, Lucio Urbani, Ferruccio Bonino, Maurizia Rossana Cancers.2021; 13(9): 2064. CrossRef
Laparoscopic bypass surgery as palliative treatment for duodenal obstruction due to lymph node metastasis invasion of hepatocellular carcinoma Akane Kurosugi, Tetsuhiro Chiba, Terunao Iwanaga, Hidemi Unozawa, Takafumi Sakuma, Naoto Fujita, Kengo Kanayama, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Soichiro Kiyono, Ryo Nakagawa, Naoya Kanogawa, Masato Nakamura, Takayuki Kondo, Tomoko Sa Kanzo.2021; 62(10): 656. CrossRef
Sorafenib Treatment has the Potential to Downstage Advanced Hepatocellular Carcinoma before Liver Resection Alessandra Bertacco, Alessandro Vitale, Claudia Mescoli, Umberto Cillo Personalized Medicine.2020; 17(2): 83. CrossRef
A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy Suguru Hirose, Kazunori Ishige, Masamichi Yamaura, Tsuneo Mizui, Yoshiki Komatsu, Masaomi Nagase, Masashi Sato, Junji Hattori, Masato Endo, Naoyuki Hasegawa, Kuniaki Fukuda, Ichinosuke Hyodo Clinical Journal of Gastroenterology.2020; 13(5): 902. CrossRef
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial Debashis Sarker, Ruth Plummer, Tim Meyer, Mikael H. Sodergren, Bristi Basu, Cheng Ean Chee, Kai-Wen Huang, Daniel H. Palmer, Yuk Ting Ma, T.R. Jeff Evans, Duncan R.C. Spalding, Madhava Pai, Rohini Sharma, David J. Pinato, James Spicer, Sarah Hunter, Vinee Clinical Cancer Research.2020; 26(15): 3936. CrossRef
Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma Mi Na Kim, Seung Min Lee, Jin Sung Kim, Seong Gyu Hwang Cancer Chemotherapy and Pharmacology.2019; 84(4): 809. CrossRef
Reversion of tumor hepatocytes to normal hepatocytes during liver tumor regression in an oncogene-expressing transgenic zebrafish model Yan Li, Ira Agrawal, Zhiyuan Gong Disease Models & Mechanisms.2019;[Epub] CrossRef
Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases Giovanni Brandi, Michela Venturi, Stefania De Lorenzo, Francesca Garuti, Giorgio Frega, Andrea Palloni, Ingrid Garajovà, Francesca Abbati, Gioconda Saccoccio, Rita Golfieri, Maria Abbondanza Pantaleo, Maria Aurelia Barbera Cancer Communications.2018; 38(1): 1. CrossRef
Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? Matthias Pinter, Wolfgang Sieghart memo - Magazine of European Medical Oncology.2018; 11(3): 185. CrossRef
First
Prev
